ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

Results from the JAVELIN Renal 101 study to evaluate avelumab plus axitinib in untreated sarcomatoid renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC) and is an aggressive form of RCC. JAVELIN […]

read more

ESMO 2019: Avelumab plus axitinib in patients who had not had nephrectomy

Results from a post-hoc analysis of JAVELIN-Renal 101 in patients with advanced renal cell carcinoma (RCC) who had not had a prior nephrectomy were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. The JAVELIN Renal 101 study demonstrated a significant improvement in progression-free survival with avelumab plus axitinib […]

read more

ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

Results from the JAVELIN-Renal 101 clinical trial to assess avelumab plus axitinib in untreated patients with advanced renal cell carcinoma (RCC) with sarcomatoid characteristics were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid RCC is an uncommon but highly aggressive form of RCC, which tends to have […]

read more

European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of the combination of avelumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This recommendation is based on findings from the phase III JAVELIN Renal 101 study involving 886 patients, which demonstrated significant improvements in median […]

read more

PD-L1 expression and clinical outcomes with targeted therapy

A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy. Positive expression of the PD-L1 receptor on RCC tumour cells was associated […]

read more

Ilixadencel plus sunitinib combination for metastatic kidney cancer

A combination of ilixadencel plus sunitinib has shown a complete tumour response in patients with metastatic renal cell carcinoma (RCC) in a recent phase 2 clinical trial. Ilixadencel is an off-the-shelf immune primer for the treatment of solid tumours. The clinical trial assessed the effectiveness of combining ilixadencel with sunitinib in 88 untreated patients with […]

read more

European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer

Based on the findings from the pivotal phase 3 KEYNOTE-426 trial, the European Commission has today approved pembrolizumab (anti-PD-1 therapy) in combination with axitinib (tyrosine kinase inhibitor) for patients with untreated, advanced renal cell carcinoma (RCC). The KEYNOTE-426 trial demonstrated a reduced risk of death by 47% with the combination compared to sunitinib in patients […]

read more

Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer

A recent study, published in Clinical Genitourinary Cancer reports a meta-analysis comparing the tolerability and efficacy of a 2 weeks on treatment/1 week off treatment sunitinib dosing schedule with the traditional 4/2 schedule in patients with metastatic renal cell carcinoma (mRCC). Data from 1173 patients were included in the meta-analysis. The study showed that progression-free […]

read more

Low PD-L1 associated with long term response to sunitinib

Researchers from France have conducted a study to show that metastatic clear cell renal cell carcinoma (RCC) patients who have low expression of PD-L1 also have a long term response to sunitinib. However, low PD-L1 levels suggest a potentially lower impact of immunotherapy in these patients. Read more in Clinical Genitourinary Cancer here

read more

SMC approves nivolumab plus ipilimumab combination for advanced RCC

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of nivolumab plus ipilimumab for intermediate-/poor-risk advanced renal cell carcinoma (RCC) by NHS Scotland. The nivolumab (Opdivo) plus ipilimumab (Yervoy) combination was accepted following consideration through the SMC’s Patient and […]

read more
Showing 21 to 30 of 118 results
  TOP